Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony Letai

Showing results (101-110 of 182) with videos related to

Pageof 19
Sort By:
Cell|February 28, 2015
Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapyJoan Montero, Kristopher A Sarosiek, Joseph D DeAngelo, et al.
American Journal of Hematology|October 29, 2020
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b studyDaniel A Pollyea, Keith Pratz, Anthony Letai, et al.
Nature Communications|November 16, 2019
Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapiesJoan Montero, Cécile Gstalder, Daniel J Kim, et al.
Nature|March 9, 2017
Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophagesJennifer L Guerriero, Alaba Sotayo, Holly E Ponichtera, et al.
Elife|April 21, 2017
Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infectionAlexander M Price, Joanne Dai, Quentin Bazot, et al.
British Journal of Haematology|February 5, 2013
KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemiaJulia Etchin, Takaomi Sanda, Marc R Mansour, et al.
Cancer Discovery|July 5, 2014
Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199Triona Ni Chonghaile, Justine E Roderick, Cian Glenfield, et al.
Breast Cancer Research : BCR|December 1, 2020
Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancerJason J Zoeller, Aleksandr Vagodny, Veerle W Daniels, et al.
Molecular Cancer Research : MCR|February 20, 2019
MCL1 and DEDD Promote Urothelial Carcinoma ProgressionAndrew L Hong, Jennifer L Guerriero, Mihir B Doshi, et al.
Blood|October 27, 2018
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemiaCourtney D DiNardo, Keith Pratz, Vinod Pullarkat, et al.
Pageof 19

Showing results (101-110 of 182) with videos related to

Sort By:
Pageof 19
Cell|February 28, 2015
Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapyJoan Montero, Kristopher A Sarosiek, Joseph D DeAngelo, et al.
American Journal of Hematology|October 29, 2020
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b studyDaniel A Pollyea, Keith Pratz, Anthony Letai, et al.
Nature Communications|November 16, 2019
Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapiesJoan Montero, Cécile Gstalder, Daniel J Kim, et al.
Nature|March 9, 2017
Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophagesJennifer L Guerriero, Alaba Sotayo, Holly E Ponichtera, et al.
Elife|April 21, 2017
Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infectionAlexander M Price, Joanne Dai, Quentin Bazot, et al.
British Journal of Haematology|February 5, 2013
KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemiaJulia Etchin, Takaomi Sanda, Marc R Mansour, et al.
Cancer Discovery|July 5, 2014
Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199Triona Ni Chonghaile, Justine E Roderick, Cian Glenfield, et al.
Breast Cancer Research : BCR|December 1, 2020
Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancerJason J Zoeller, Aleksandr Vagodny, Veerle W Daniels, et al.
Molecular Cancer Research : MCR|February 20, 2019
MCL1 and DEDD Promote Urothelial Carcinoma ProgressionAndrew L Hong, Jennifer L Guerriero, Mihir B Doshi, et al.
Blood|October 27, 2018
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemiaCourtney D DiNardo, Keith Pratz, Vinod Pullarkat, et al.
Pageof 19